Clinical Trials Logo

Stage IV Non-small Cell Lung Cancer clinical trials

View clinical trials related to Stage IV Non-small Cell Lung Cancer.

Filter by:

NCT ID: NCT03119519 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Local Non-salvage Radiotherapy for Synchronous Oligometastatic Non-small-cell Lung Cancer.

Start date: December 11, 2017
Phase: Phase 2
Study type: Interventional

Aggressive therapy may improve survival in synchronous oligometastatic NSCLC and the goal of this clinical trial is to assess the efficacy and safety of local definitive radiotherapy in this subset of patients.

NCT ID: NCT03087708 Recruiting - Clinical trials for Stage IV Non-small Cell Lung Cancer

Naloxegol in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Start date: October 13, 2017
Phase: Phase 2
Study type: Interventional

This randomized pilot clinical trial studies the side effects and best dose of naloxegol and to see how well it works in treating patients with stage IIIB-IV non-small cell lung cancer. Naloxegol may relieve some of the side effects of opioid pain medication and fight off future growth in the cancer.

NCT ID: NCT03049618 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Recombinant EphB4-HSA Fusion Protein and Pembrolizumab, MK-3475

Start date: March 10, 2017
Phase: Phase 2
Study type: Interventional

This phase IIa trial studies how well recombinant EphB4-HSA fusion protein and pembrolizumab work in treating patients with non-small cell lung cancer that has spread to other places in the body or head and neck squamous cell cancer that has come back or spread to other places in the body. Recombinant EphB4-HSA fusion protein may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of cancer cells to grow and spread. Giving recombinant EphB4-HSA fusion protein and pembrolizumab may work better in treating patients with non-small cell lung or head and neck squamous cell cancer.

NCT ID: NCT03048500 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Nivolumab and Metformin Hydrochloride in Treating Patients With Stage III-IV Non-small Cell Lung Cancer That Cannot Be Removed by Surgery

Start date: June 6, 2017
Phase: Phase 2
Study type: Interventional

The purpose of this study is to find the benefits of combining nivolumab with metformin in advanced non-small cell lung cancer with and without prior treatment with immunotherapy. We will also be looking at the safety of the combination. Nivolumab is currently approved in certain cancers such as melanoma, lung cancer and kidney cancer. Metformin is approved by the US Food and Drug Administration (FDA) to treat diabetes. In this study, Metformin is being used to treat cancer. This use is not approved by the FDA; therefore, in this study, it is considered experimental. Experimental means the U.S. FDA has not approved the drug for use in your type of cancer. Nivolumab is an antibody (a human protein that sticks to a part of the tumor and/or immune cells) designed to allow the body's immune system to work against tumor cells. It is believed that metformin has immune modifying properties, meaning it can boost your immune system. As a result, it may help certain cancer treatments, known as immunotherapy, to work better.

NCT ID: NCT03023904 Withdrawn - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Nivolumab in Treating Patients With Stage IV or Recurrent Lung Cancer With High Mutation Loads

Start date: December 29, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well nivolumab works in treating patients with stage IV lung cancer or that has come back after initial treatment who has high mutation loads. Monoclonal antibodies, such as nivolumab, may block tumor growth in different ways by targeting certain cells.

NCT ID: NCT02955290 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

CIMAvax Vaccine and Nivolumab in Treating Patients With Stage IIIB-IV Non-small Cell Lung Cancer

Start date: December 9, 2016
Phase: Phase 1/Phase 2
Study type: Interventional

This partially randomized phase I/II trial studies the best dose and side effects of recombinant human EGF-rP64K/montanide ISA 51 vaccine (CIMAvax) and nivolumab and to see how well they work in treating patients with stage III-IV non-small cell lung cancer. Vaccine therapy, such as CIMAvax vaccine may help slow down and stop tumor growth. Monoclonal antibodies, such as nivolumab, may block a protein needed by tumor cells to grow and spread. Giving CIMAvax vaccine together with nivolumab may work better in treating patients with stage IIIB-IV non-small cell lung cancer.

NCT ID: NCT02949843 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations

Start date: March 10, 2017
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well targeted therapy works in treating patients with incurable non-small cell lung cancer with a genetic mutation. Giving drugs that target other genetic mutations or other specific proteins may work better when a patient has cancer caused by a driver mutation and the treatment that targets that mutation stops working.

NCT ID: NCT02947386 Recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer

Start date: June 29, 2017
Phase: Phase 1/Phase 2
Study type: Interventional

This phase I/II trial studies the best dose and side effects of nimotuzumab when giving together with nivolumab and to see how well they work in treating patients with non-small cell lung cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment. Monoclonal antibodies, such as nimotuzumab and nivolumab, may block tumor growth in different ways by targeting certain cells.

NCT ID: NCT02897375 Recruiting - Colorectal Cancer Clinical Trials

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Start date: October 2016
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of palbociclib with cisplatin or carboplatin in treating patients with solid tumors that have spread to other places and usually cannot be cured or controlled with treatment. Palbociclib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving palbociclib with cisplatin or carboplatin may help stop tumor growth in patients with advanced solid tumors.

NCT ID: NCT02879994 Active, not recruiting - Clinical trials for Stage IV Non-Small Cell Lung Cancer

Pembrolizumab in Treating Patients With EGFR Mutant, Tyrosine Kinase Inhibitor Naive Advanced Non-Small Cell Lung Cancer

Start date: September 15, 2016
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well pembrolizumab works in treating patients with epidermal growth factor receptor (EGFR) mutant non-small cell lung cancer that have not received prior tyrosine kinase inhibitor therapy and has spread to other places in the body. Monoclonal antibodies, such as pembrolizumab, may block growth in different ways by targeting certain cells.